This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Post #27 describes the usual case. This is about the unusual one.
Oral versus injectable exposure is worth one more sentence than it usually gets, and the sentence is the one about how the number was arrived at.
Fasting instructions are not optional advice. Taking the tablet with food or with more than a sip of water measurably reduces absorption. This is the one compound in the class where the instructions genuinely determine the exposure.
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
SNAC and the mechanism of oral peptide absorption
On the subject in the title: SNAC and the mechanism of oral peptide absorption Working notes rather than a conclusion. A comparison question rather than a question about one compound. Two things in the same…
|
+13 | 17 | 14k | 17mo |
|
Why an oral GLP-1 agonist is a formulation achievement more than a chemistry one
Why an oral GLP-1 agonist is a formulation achievement more than a chemistry one I have a specific reason for asking rather than idle curiosity, and the context is below. A methods question rather than a…
|
+130 | 135 | 11k | 7mo |
|
Coming back to: The SOUL trial and oral semaglutide cardiovascular outcomes
The SOUL trial and oral semaglutide cardiovascular outcomes — setting out what I have, and where I think it stops being reliable. SOUL trial and oral semaglutide — I have the observation and I do not trust my…
|
+100 | 104 | 4.2k | 5mo |
|
PIONEER 6 cardiovascular safety, read as a safety trial rather than an efficacy one
PIONEER 6 cardiovascular safety, read as a safety trial rather than an efficacy one — setting out what I have, and where I think it stops being reliable. Posting a small dataset on PIONEER 6 cardiovascular…
|
+25 | 29 | 22k | 1d |
|
Orforglipron as a non-peptide: what changes when the molecule is small
On the subject in the title: Orforglipron as a non-peptide: what changes when the molecule is small Working notes rather than a conclusion. What changes if the standard account of orforglipron is wrong? I ask…
|
+26 | 30 | 26k | 23mo |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
[2026 update] Tirzepatide in obstructive sleep apnoea: reading SURMOUNT-OSA
Tirzepatide in obstructive sleep apnoea: reading SURMOUNT-OSA — setting out what I have, and where I think it stops being reliable. Reading back through what has been written here about Tirzepatide in…
|
2 | 58k | 11mo | |
|
Why oral semaglutide needs an absorption enhancer at all — one year on
Why oral semaglutide needs an absorption enhancer at all — one year on — that is the question, and I have not found it answered plainly anywhere I have looked. Reading back through what has been written here…
|
+11 | 15 | 17k | 24d |
|
What TRIUMPH is designed to answer, and why we should not pre-empt it — does this still hold?
Asking directly, because I could not find a straight answer: What TRIUMPH is designed to answer, and why we should not pre-empt it — does this still hold? An honest uncertainty about TRIUMPH rather than a…
|
+43 | 47 | 5.5k | just now |
|
Second pass at: Triple agonism: additive, synergistic, or neither?
Second pass at: Triple agonism: additive, synergistic, or neither? — that is the question, and I have not found it answered plainly anywhere I have looked. Posting a small dataset on Triple agonism. It is…
|
+114 | 120 | 1.4k | 10mo |
|
Journal club: STEP 3 and the intensive behavioural therapy floor
Posting this under the heading it deserves: Journal club: STEP 3 and the intensive behavioural therapy floor Everything below is what sits behind that. Two things I would like separated before anyone answers…
|
+6 | 10 | 13k | 28d |